CanSino Biologics Initiates Phase II/III Trial for Tdcp Adolescent and Adult Vaccine

• CanSino Biologics has commenced a Phase II/III clinical trial for its Tdcp Adolescent and Adult vaccine, targeting individuals aged six years and older.
• The Tdcp vaccine is designed as a booster for diphtheria, tetanus, and pertussis, addressing a gap in the Chinese market where no approved booster exists for adolescents and adults.
• The vaccine utilizes separately purified pertussis antigens, formulated in a defined ratio to ensure consistent product quality and enhanced stability.
• Successful development of this vaccine aims to fill the domestic market void, aligning China with routine vaccination programs in major developed countries.

CanSino Biologics Inc. has announced the initiation of a Phase II/III clinical trial for its absorbed diphtheria, tetanus and acellular pertussis (components) combined vaccine (Tdcp Adolescent and Adult). This vaccine is intended for individuals aged six years and above and marks a significant step towards addressing an unmet medical need in China.

The Tdcp Adolescent and Adult vaccine serves as a booster for diphtheria, tetanus, and pertussis. While many developed nations have integrated such vaccines into their standard immunization schedules, China currently lacks an approved booster vaccine for these diseases in adolescents and adults. The successful introduction of CanSino Biologics' Tdcp vaccine is poised to bridge this gap in the domestic market.

The manufacturing process of the Tdcp Adolescent and Adult vaccine distinguishes itself from existing co-purified vaccines in China. Instead of co-purifying pertussis antigens, each antigen in CanSino's vaccine is purified separately and then combined in a precise ratio. This approach ensures batch-to-batch consistency in product quality and enhances the overall stability of the vaccine.